Trials / Completed
CompletedNCT00160511
A 16 Week Study Evaluating Levetiracetam in the Treatment of Post Herpetic Neuralgia (PHN)
A Double-blind, Randomized, Placebo-controlled, Parallel-group, 16 Week, Multicenter Trial Evaluating the Efficacy and Safety of Levetiracetam 500 mg Tablets in Bid Administration (Daily Dose Ranging From 1000 mg to 3000 mg), in Adults (≥ 18 Years of Age) Suffering From Postherpetic Neuralgia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 170 (planned)
- Sponsor
- UCB Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
16 week trial assessing the efficacy, safety, and tolerability of levetiracetam compared with placebo in the treatment of postherpetic neuralgia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Levetiracetam |
Timeline
- Start date
- 2004-04-01
- Primary completion
- 2005-08-01
- Completion
- 2005-09-01
- First posted
- 2005-09-12
- Last updated
- 2013-11-26
Source: ClinicalTrials.gov record NCT00160511. Inclusion in this directory is not an endorsement.